watching closely, page-38

no, I think all the participants, placebo or PBT2, will get PBT2 after 12 months...

"All participants in the extension study will receive a 250mg once daily oral dose of PBT2 for an additional 12 months, with the first patient expected to start next month."

For me, the critical thing here is that this has come from the Ethics Committee.

If you have a drug that appears to be delivering some benefits, and is not inducing adverse effects, then there would be a certain ethical obligation to have the trial continue - open label - for all participants.

But I might be misguided here. The trial is 'double blinded', so neither the participants or the doctors know who is receiving placebo and who is receiving PBT2. But does that mean no one, including the ethics committee, can know if any of the scans are showing benefits?